Tabercrassine B






Names

    • Tabercrassine B

Attributes

  • Canonical SMILES

    O=C(OC)[C@]([C@H]1[N@@]([C@@H]2CC(CC(C)(O)C)=O)CC3)(C[C@@]2([H])C[C@@H]1CC)C4=C3C(C=C(OC)C=C5)=C5N4

  • InChI

    InChI=1S/C28H38N2O5/c1-6-16-11-17-14-28(26(32)35-5)24-20(21-13-19(34-4)7-8-22(21)29-24)9-10-30(25(16)28)23(17)12-18(31)15-27(2,3)33/h7-8,13,16-17,23,25,29,33H,6,9-12,14-15H2,1-5H3/t16-,17+,23+,25-,28+/m0/s1

  • Molecule Class: Alkaloids
  • TPSA: 91.86000000000001
  • #RotBonds: 7
  • MW: 482.62100000000027
  • HBD: 2
  • HBA: 6
  • logP: 3.752600000000002
  • Chemical Formula: C28H38N2O5


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. crassa Ghana 761062 20161116

External Databases


References

  • New Monoterpenoid Indole Alkaloids from Tabernaemontana crassa Inhibit β-Amyloid42 Production and Phospho-Tau (Thr217). Int J Mol Sci, 2023 (PMID 36675001).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Cytotoxicity

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -4.95
    Human Oral Bioavailability 20% Non-Bioavailable
    Human Intestinal Absorption Absorbed
    Madin-Darby Canine Kidney -4.87
    Human Oral Bioavailability 50% Non-Bioavailable
    P-Glycoprotein Inhibitor Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability -0.42
    Distribution Blood-Brain Barrier (Central Nervous System) -3.22
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 0.97
    Plasma Protein Binding 69.98
    Steady State Volume of Distribution 3.31
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Non-Inhibitor
    CYP 1A2 substrate Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Non-Substrate
    CYP 3A4 Inhibitor Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Non-Inhibitor
    Excretion Clearance 7.98
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Safe
    Bee Toxic
    Bioconcentration Factor -0.49
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -1.06
    Liver Injury II Toxic
    hERG Blockers Safe
    Daphnia Maga 8.56
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Toxic
    T. Pyriformis -397.71
    Rat (Acute) 3.2
    Rat (Chronic Oral) 1.77
    Fathead Minnow 4.26
    Respiratory Disease Toxic
    Skin Sensitisation Safe
    SR-ATAD5 Safe
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe
    General Properties Boiling Point 488.62
    Hydration Free Energy -2.83
    Log(D) at pH=7.4 3.57
    Log(P) 2.99
    Log S -3.87
    Log(Vapor Pressure) -9.66
    Melting Point 201.98
    pKa Acid 7.89
    pKa Basic 6.36